Kybernin P (Antithrombin Iii)

Antithrombin III is a natural inhibitor of several clotting enzymes, most importantly thrombin (factor IIa) and factor Xa. By binding to these enzymes, it blocks their activity, reducing the conversion of fibrinogen to fibrin and thereby limiting clot formation. Kybernin P supplies exogenous antithrombin III, enhancing this inhibitory pathway in patients who lack sufficient endogenous protein.

The dose of Kybernin P is individualized. A prescribing clinician determines the amount based on the patient’s measured antithrombin activity, body weight, the clinical situation (e.g., surgery, trauma, heparin resistance), and target antithrombin levels. Dosing regimens are therefore set by the treating physician and may be adjusted during therapy.

Safety data for Kybernin P in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and follow local regulatory guidance regarding use of antithrombin concentrates during pregnancy or while nursing.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Kybernin P is a plasma‑derived antithrombin concentrate offering a high purity and standardized activity. Compared with fresh‑frozen plasma, it provides a more concentrated and predictable antithrombin dose with lower volume load. Alternative concentrates from other manufacturers have similar mechanisms, but differences may exist in viral inactivation processes, excipients, and storage requirements.

Kybernin P must be stored refrigerated at 2 °C to 8 °C. The vial should remain in its original container, protected from light, and must not be frozen or shaken. Prior to administration, allow the product to reach room temperature if required by the label, and inspect for any particulate matter or discoloration before use.

Kybernin P is given by intravenous infusion. The prescribed dose is diluted in an appropriate compatible solution and infused over a period defined by the treating physician, often under close monitoring of antithrombin activity and coagulation parameters. Infusion rates may be adjusted based on patient tolerance and laboratory results.

The most serious adverse events include severe allergic reactions such as anaphylaxis, paradoxical thrombotic events, and uncontrolled bleeding. Clinicians should monitor patients closely for signs of hypersensitivity, sudden drops in blood pressure, new clot formation, or excessive hemorrhage, and be prepared to intervene promptly.

Kybernin P is contraindicated in individuals with a known hypersensitivity to antithrombin concentrates or any component of the formulation. It should also be avoided in patients with active, uncontrolled bleeding or severe coagulopathy where further anticoagulation could exacerbate hemorrhage. Clinical judgment is required for patients with recent major surgery or those receiving